For the year ending 2025-12-31, RMTI had -$4,951K decrease in cash & cash equivalents over the period. -$1,201K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -5,314 |
| Depreciation and amortization | 2,192 |
| Stock-based compensation | 1,816 |
| Write-off of inventory | 178 |
| Change in inventory reserves | -425 |
| Non-cash lease expense from right of use assets | 2,141 |
| Amortization of debt financing costs and accretion of debt discount and premium | 354 |
| Loss on disposal of assets | -57 |
| Realized gain on sale of investments | 267 |
| Gain on early termination of lease liability | 24 |
| Provision for credit losses | 246 |
| Accounts receivable | 98 |
| Inventory | -2,779 |
| Prepaid and other assets | -392 |
| Accounts payable | -870 |
| Lease liabilities | -1,662 |
| Accrued and other liabilities | -1,679 |
| Deferred license revenue | -475 |
| Changes in operating assets and liabilities | 1,613 |
| Net cash (used in) provided by operating activities | -659 |
| Purchases of investments available-for-sale | 24,202 |
| Proceeds from sales of investments available-for-sale | 16,200 |
| Purchases of equipment | 542 |
| Net cash used in investing activities | -8,544 |
| Payments on insurance financing note payable | 664 |
| Payments on finance lease liabilities | 529 |
| Proceeds from issuance of common stock | 7,816 |
| Deferred consideration paid in connection with evoqua asset acquisition | 2,371 |
| Net cash provided by financing activities | 4,252 |
| Effect of exchange rate changes on cash and cash equivalents | 0 |
| Net (decrease) increase in cash and cash equivalents | -4,951 |
| Cash and cash equivalents at beginning of year | 15,662 |
| Cash and cash equivalents at end of year | 10,711 |
ROCKWELL MEDICAL, INC. (RMTI)
ROCKWELL MEDICAL, INC. (RMTI)